

9th INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

MONACO, 11-13 NOVEMBER, 2009



www.ifmad.org

M.C. Escher "The Knot"



Final Programme



SCIENTIFIC COMMITTEE

Chairman

Siegfried Kasper (*Austria*)

Co-Chairman

Stuart A. Montgomery (*United Kingdom*)

Scientific Advisers

C. Allgulander (*Sweden*), C.A. Altamura (*Italy*), C. Arango (*Spain*),
D. Baldwin (*United Kingdom*), M. Bauer (*Germany*), P. Boyer (*Canada*),
G. Burrows (*Australia*), G. B. Cassano (*Italy*), K. Demyttenaere (*Belgium*),
J. Den Boer (*The Netherlands*), T. Dinan (*Ireland*), E. Eriksson (*Sweden*),
N. Fineberg (*United Kingdom*), T. Higuchi (*Japan*), S. H. Kennedy (*Canada*),
J.P. Lépine (*France*), M. Maj (*Italy*), A.A. Mathé (*Sweden*), J. Mendlewicz (*Belgium*),
H.J. Moeller (*Germany*), S. Pallanti (*Italy*), G. Papadimitriou (*Greece*),
G. Papakostas (*USA*), Z. Rihmer (*Hungary*), A. F. Schatzberg (*USA*),
D.J. Stein (*South Africa*), T. Suppes (*USA*), E. Vieta (*Spain*),
L. Von Knorring (*Sweden*), D. Winkler (*Austria*),
S. Yamawaki (*Japan*), J. Zohar (*Israel*)

IMPORTANT ADDRESSES

Organizing Secretariat



PUBLI CREATIONS - Partner of AIM

74, Bd d'Italie - 98000 Monte-Carlo - Monaco

Ph. +377 97973555 - Fax +377 97973550

E-mail: ifmad@publiccreations.com

Website: www.ifmad.org

Forum Venue



Hôtel FAIRMONT

12, Av. des Spéluges

98000 Monaco

Tel. + 377 93506500



Acknowledgement **4**

Welcome Letter **5**

Programme Overview **6**

Scientific Programme **7**

Posters **12**

Scientific Information **20**

General Information **20**

Announcement Next Forum **22**

www.ifmad.org





Dear IFMAD Forum Participants,

We are delighted to welcome you to Monaco on the occasion of the “9th IFMAD Forum” and we wish you a very successful meeting. We hope that you will find the time to discover or re-discover Monaco’s historical areas, gardens, shopping malls and museums.

Thank you for selecting the Principality of Monaco for your prestigious event.

Should you need any assistance during your stay, please do not hesitate to contact the Monaco Tourist Office.

Kindest regards.

Michel BOQUIER
President Monaco Tourism
and Convention Authority

ACKNOWLEDGEMENT

*The Organising Committee
express their gratitude to the following Companies*

LUNDBECK A/S

PIERRE FABRE

for their contribution as Sponsor of Symposia

PFIZER

as Sponsor to the Programme

WISEPRESS LTD

for their participation in the exhibition



The International Forum on Mood and Anxiety Disorders (IFMAD) will be held from 11 to 13 November 2009 in Monte-Carlo, Monaco.

The most useful feature about IFMAD meetings is that current clinical hot topics and new data are presented in a balanced format, adequately dissected and discussed in a collegial atmosphere, and digested over dinner. The meetings are always enjoyable and informative.

This year a large number of key areas are addressed such as questioning why pharmacological treatments are under attack, whether the new data in bipolar depression will shift the approach towards treatment, the increasing restrictions on prescribing medication for adolescents and elderly patients and a debate with a member of the CHMP on whether the EU is too restrictive in licensing medications for CNS. The new data on treatment resistant depression and the advances in PTSD will be challenged and the implications of new data on the potentially evolving role of atypicals in anxiety and depression will be discussed.

Along with the usual updates on new treatments in other areas this year's IFMAD will be an efficient way of catching up with the latest developments.

We invite you to join us again in November 2009 to give you the opportunity to keep abreast of the latest advances in psychiatry. It will be our pleasure to welcome you in Monte-Carlo.

Siegfried Kasper, Chairman

Stuart A. Montgomery, Co-Chairman



PROGRAMME OVERVIEW

Wednesday, November 11	Thursday, November 12	Friday, November 13
	09.00/10.30 Using the latest evidence to its full potential in the treatment of depression and anxiety	09.00/10.30 Bipolar Disorder - Myths and Evidence
	10.30/11.00 <i>Coffee break</i>	10.30/11.00 <i>Coffee break</i>
	11.00/12.30 Recent Advances in the Treatment of GAD	11.00/12.30 Psychopharmacology in the life span
14.30/16.00 Difficulties in Treatment of Resistant Depression	12.30/13.30 <i>Lunch</i>	12.30/13.30 <i>Lunch</i>
16.00/16.30 <i>Coffee break</i>	13.30/15.00 Pharmacological Treatment under Attack	13.30/15.00 Future Developments in Depression and Anxiety
16.30/18.00 Advances in Treating Post Traumatic Stress Disorder (PTSD)	15.00/16.00 Debate: Are we too restrictive in licensing CNS drugs in Europe?	15.00/16.30 New Focuses on treatment
18.00/19.00 <i>Opening Ceremony</i>	16.00/16.30 <i>Coffee break</i>	16.30/16.45 End of meeting
19.00/20.00 Update on the Psychiatric Department of the Princesse Grace Hospital in Monaco	16.30/18.00 Milnacipran: Recent Findings in Depression	





WEDNESDAY, 11 November 2009

14.30 - 16.00 SO 01 - DIFFICULTIES IN TREATMENT OF RESISTANT DEPRESSION

Chair: **D. Souery (Belgium)**

- SO 0101 TRD - The concept, the staging and the predictors
Joseph Zohar (Israel)
- SO 0102 Response and Remission rates RN Treatment Resistant Depression: interim results from an open study of the efficacy of Escitalopram in Treatment Resistant Depression
Daniel Souery (Belgium)
- SO 0103 Management of TRD - **Stuart Montgomery (UK)**

16.00 - 16.30 Coffee break

16.30 - 18.00 SO 02 - ADVANCES IN TREATING POST TRAUMATIC STRESS DISORDER (PTSD)

Chair: **J. Davidson (USA)**

- SO 0201 Shifting the focus towards preventing PTSD
Joseph Zohar (Israel)
- SO 0202 Pharmacological treatment of PTSD
Jonathan Davidson (USA)
- SO 0203 PTSD after the 2003 Iraq War: the UK story
Dominic Murphy (UK)

18.00 - 19.00 Opening Ceremony

19.00 - 20.00 Update on the Psychiatric Department of the Princesse Grace Hospital in Monaco *(This session is held in French)*

- Comment améliorer l'observance du traitement dans dépression - **Joséphine Loftus (Monaco)**
- Prise en charge de l'addictologie au CHPG
Ségolène Moulierac (Monaco)
- Prise en charge extra-hospitalière à Monaco par l'unité mobile de PSY - **Céline Plasseraud (Monaco)**
- Place de l'équipe de psychiatrie de liaison au sein du CHPG de MONACO
Irène Cussac, Khaled Kammoun (Monaco)



SCIENTIFIC PROGRAMME

THURSDAY, 12 November 2009

09.00 - 10.30 SO 03 - USING THE LATEST EVIDENCE TO ITS FULL POTENTIAL IN THE TREATMENT OF DEPRESSION AND ANXIETY

Chair: **S. Kasper (Austria)**

SO 0301 Remission: achieving and sustaining the optimal outcome
Yoram Barak (Israel)

SO 0302 Anxiety - a predictor of treatment success in major depressive disorder?
Siegfried Kasper (Austria)

SO 0303 Findings solutions for late life depression
Rob Kok (The Netherlands)

Symposium sponsored by an unrestricted educational grant from H. Lundbeck A/S

10.30 - 11.00 **Coffee break**

11.00 - 12.30 SO 04 - RECENT ADVANCES IN THE TREATMENT OF GAD

Chair: **D. Baldwin (UK)**

SO 0401 Suicide and Anxiety
Zoltan Rihmer (Hungary)

SO 0402 Benzodiazepine and pregabalin in the Treatment of GAD
Jill Rasmussen (UK)

SO 0403 Antipsychotic drugs in the Treatment of GAD
David Baldwin (UK)

12.30 - 13.30 **Lunch**



13.30 - 15.00 **SO 05 - PHARMACOLOGICAL TREATMENT UNDER ATTACK**

Chair: **K. Demyttenaere (Belgium)**

- SO 0501 Why are there so few new treatments
Filippo Drago (Italy)
- SO 0502 Pharmacological treatment of depression under attack
Koen Demyttenaere (Belgium)
- SO 0503 Of course antidepressants work and are they value for money?
Tim Bullock (UK)

15.00 - 16.00 **SO 06 - DEBATE: ARE WE TOO RESTRICTIVE IN LICENSING CNS DRUGS IN EUROPE?**

Chair: **S. Kasper (Austria)**

Pro: **Stuart Montgomery (UK)**

Contra: **Karl Broich (Germany)**

16.00 - 16.30 **Coffee break**

16.30 -18.00 **SO 07 - MILNACIPRAN: RECENT FINDINGS IN DEPRESSION**

Chair: **S. Montgomery (UK)**

- SO 0701 Milnacipran: a unique antidepressant
Siegfried Kasper (Austria)
- SO 0702 Suicidality: the positive effect of milnacipran
Philippe Courtet (France)
- SO 0703 Using flexible dosing with milnacipran and venlafaxine
Lucilla Mansuy (France)
- SO 0704 Improvement of depressive and diabetic symptoms with milnacipran in co-morbid patients
Peter Hofmann (Austria)

Symposium sponsored by an unrestricted educational grant from Pierre Fabre Medicaments



FRIDAY, 13 November 2009

**09.00 - 10.30 SO 08 - BIPOLAR DISORDER
MYTHS AND EVIDENCE**

Chair: ***E. Vieta (Spain)***

SO 0801 Are antidepressants useful in treating bipolar depression?

Eduard Vieta (Spain)

SO 0802 The role of atypical antipsychotics in treating bipolar and unipolar depression

Hans Eriksson (Sweden)

SO 0803 Optimal maintenance treatment for bipolar disorder

Michael Bauer (Germany)

10.30 - 11.00 Coffee break

**11.00 - 12.30 SO 09 - PSYCHOPHARMACOLOGY
IN THE LIFE SPAN**

Chair: ***R. Buller (Germany)***

SO 0901 ADHD over the life span:
clinical and neurobiological aspects

Jan K. Buitelaar (The Netherlands)

SO 0902 Genetics of ADHD

Johannes Thome (UK)

SO 0903 Are restrictions on psychotropics in adolescents and the elderly justified?

Raimond Buller (Germany)

12.30 - 13.30 Lunch



13.30 - 15.00 SO 10 - FUTURE DEVELOPMENTS IN DEPRESSION AND ANXIETY

Chair: **A. Mathé (Switzerland)**

SO 1001 Animal models for depression and anxiety -
are they sufficiently predictive?

Alexander Mathé (Switzerland)

SO 1002 Possible influence of 5HTTLPR polymorphism on treatment

Alessandro Serretti (Italy)

SO 1003 Update on treatment of depression
and anxiety in schizophrenia

Patrice Boyer (France)

15.00 - 16.30 SO 11 - NEW FOCUSES ON TREATMENT

Chair: **Z. Rihmer (Hungary)**

SO 1101 Hormonal or serotonergic treatments for PMDD

Elias Eriksson (Sweden)

SO 1102 Treating insomnia in comorbid disorders

Malcom Lader (UK)

SO 1103 Managing the risk of suicide in depression

Zoltan Rihmer (Hungary)

16.30 - 16.45 End of meeting



P 01. Diabetes mellitus and co-morbid depression: treatment with Milnacipran results in significant improvement of both diseases

H. Abrahamian¹, P. Hofmann², R. Prager¹, H. Toplak³

¹General Hospital Hietzing with Neurological Center Rosenhügel and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Vienna, Austria; ²Department of Psychiatry, University Hospital, Graz, Austria; ³Department of Internal Medicine, University Hospital, Graz, Austria

P 02. Comorbidity of anxiety and depression with dermatological conditions

A. Afkham Ebrahimi¹, SH Afkham Ebrahimi²

¹Iran University of Medical Sciences, Tehran, Iran; ²Tehran University, Tehran, Iran

P 03. The effect of Milnacipran on suicidality in patients with mild to moderate depressive disorder

A. Avedisova, V. Borodin, K. Zakharova, A. Aldushin

Department of Borderline Psychiatry, FGU State Scientific Research Center of Social and Forensic Psychiatry «V.P. Serbsky», Moscow, Russia

P 04. Sustained response with adjunctive extended release quetiapine fumarate (quetiapine XR): pooled efficacy analysis in major depressive disorder (MDD)

M. Bauer¹, E. Vieta², W. Earley³, J. Szamosi⁴, H.A. Eriksson⁴

¹University Hospital Carl Gustav Carus, Dresden, Germany; ²Institute of Clinical Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; ³AstraZeneca Pharmaceuticals, Wilmington, USA; ⁴AstraZeneca R&D, Södertälje, Sweden

P 05. Heterogeneity of depressive disturbances in alcoholism with co-morbid organic mood disorder: possibilities of paroxetine

N. Bokhan

Mental Health Research Institute, Tomsk, Russia

P 06. Psychological determinants of anxiousness in population living in zone of ecological risk

T. Bokhan

Tomsk State University, Tomsk, Russia

P 07. The epidemiology of depression and suicidal behaviour in Slovakia

D. Breznoscakova¹, J. Dragasek²

¹University of P. J. Safarik, School of Medicine, 1st Dept. of Psychiatry, Kosice, Slovak Republic;

²Faculty Hospital of L. Pasteur, 1st Dept. of Psychiatry, Kosice, Slovak Republic

P 08. Vagus nerve stimulation in treatment-resistant depression: an Italian case-series

M. Buoli, L. Oldani, M. Serati, A. Albano, M. Ciabatti, B. Dell'Osso, A.C. Altamura

Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Department of Psychiatry, Milan, Italy



P 09. Psychiatric comorbidity in bipolar disorder: which associations prevail in different age groups

M. Buoli, S. Bortolussi, L. Oldani, M.C. Palazzo, G. Camuri, B. Benatti, B. Dell'Osso, A.C. Altamura

Department of Psychiatry, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy

P 10. Effects of duloxetine adjunctive to extended-release quetiapine treatment in bipolar I mixed - an open label study

G. Callista¹, E. Daneluzzo²

¹U.O. Psichiatria ASL Teramo, Giulianova (TE), Italy; ²SPDC ASLCN2, Alba (CN), Italy

P 11. Repeated transcranial magnetic stimulation (rTMS) treatment for refractory obsessive-compulsive disorder

J. Chae, S. Lee, J. Jeong, H. Seo

Dept. of Psychiatry, The Catholic University of Korea, Seoul, South Korea

P 12. Early remission as predictor of good outcome in the prognosis of a major depressive episode: its neurobiological implications

E. Alvarez¹, I. Gilaberte², L. Caballero³, E. Baca³, M. Roca⁴, M. Casillas², P. Garcia de Polavieja², A. Gervas², A. Valladares², B. Yruretagoyena², A. Ciudad²

¹Department of Psychiatry, Hospital Santa Creu i Sant Pau., Barcelona, Spain; ²Lilly Clinical Research Department, Alcobendas, Spain; ³Department of Psychiatry, Hospital Puerta de Hierro, Madrid, Spain; ⁴Department of Psychiatry, Hospital Joan March, Palma de Mallorca, Spain

P 13. Effects of milnacipran, duloxetine and pregabalin on the changes in BDNF levels elicited by repeated restraint stress in the rat

C. Cosi¹, L. Bardin², M. Marien¹, S. Boyer¹, R. Deportere², A. Newmann-Tancredi²

¹Division of Neurobiology 1, Institut de Recherche Pierre Fabre, Castres, France; ²Division of Neurobiology 2, Institut de Recherche Pierre Fabre, Castres, France

P 14. Differentiated information on antidepressants at hospital discharge: the GIPPOZ-study

F. Desplenter¹, G. Laekeman¹, Vza Psychiatry², S. Simoens¹

¹Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, Leuven, Belgium; ²Psychiatric Hospital Sint Jan, Eeklo, Belgium

P 15. Discharge management for patients in Flemish psychiatric hospitals

F. Desplenter¹, G. Laekeman¹, P. Moons², S. Simoens¹

¹Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, Leuven, Belgium; ²Katholieke Universiteit Leuven, Centre for Health Services and Nursing Research, Leuven, Belgium



P 16. Quetiapine in the treatment of bipolar depression: improvements in quality of life and functioning in four randomized, placebo-controlled trials

L. Fautrao, U. Gustafsson, B. Paulsson, H. Eriksson

AstraZeneca R&D, Södertälje, Sweden

P 17. Antidepressant-like effect of SCH-23390 in combination with sub-active dose of 17B-estradiol in ovariectomized rats

J. Fedotova, N. Ordayn

I.P. Pavlov Institute of Physiology RASci., St. Petersburg, Russia

P 18. Pharmaceutical care for patients with depression: a survey of pharmacists' attitudes, current practices and barriers

V. Foulon¹, S. Liekens¹, M. Wouters¹, G. Scheerder², G. Laekeman¹, T. Smits³

¹Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, K.U. Leuven, Leuven, Belgium; ²LUCAS, Centre for Research and Consultancy, Leuven, Belgium; ³European Centre for Ethics, Leuven, Belgium

P 19. Impact of regulatory safety warnings on the use of antidepressants among children and adolescents in Finland

V. Foulon¹, A. Svala², I. Koskinen³, T. Chen⁴, I. Saastamoinen⁵, S. Bell^{2,4,5,6}

¹Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, K.U. Leuven, Leuven, Belgium; ²Division of Social Pharmacy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; ³Research Department, Social Insurance Institution, Helsinki, Finland; ⁴Faculty of Pharmacy, University of Sydney, Sydney, Australia; ⁵Department of Pharmacology and Toxicology, University of Kuopio, Kuopio, Finland; ⁶Kuopio Research Centre of Geriatric Care, University of Kuopio, Kuopio, Finland

P 20. Depression is a major cause of internet addiction in adolescents and young adults; 2 years experience in an internet addiction clinic

J. Ha¹, J. Yu², D.H. Park³, W. Lim⁴

¹Department of Psychiatry, School of Medicine, Konkuk University, Seoul, South Korea; ²Department of Psychiatry, College of Medicine, Ewha Womans University, Seoul, South Korea

P 21. Natural killer T cell in depressed patients treated with SSRIs

S. Han, Y.H. Jeon, E.J. Park

Department of Psychiatry, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, South Korea

P 22. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich antidepressant response signature project

J. Hennings¹, T. Owashi², E. Binder¹, S. Horstmann¹, A. Menke¹, S. Kloiber¹, T. Dose¹, B. Wollweber¹, D. Spieler¹, T. Messer³, H. Künzel⁴, T. Bierner⁴, T. Pollmächer⁴, H. Pfister¹, T. Nickel¹, A. Sonntag¹, M. Uhr¹, M. Ising¹, F. Holsboer¹, S. Lucae¹

¹Max Planck Institute of Psychiatry, Munich, Germany; ²Department of Psychiatry, Showa University Fujigaoka Hospital, Yokohama, Japan; ³Bezirkskrankenhaus Augsburg, Augsburg, Germany; ⁴Klinikum Ingolstadt, Ingolstadt, Germany



P 23. The TREK-1 potassium channel as a new antidepressant target
M. Borsotto¹, M. Blondeau¹, G. Lucas², N. Guy¹, M. El-Yacoubi³, F. Noble⁴, C. Widmann¹, J.M. Vaugeois³, M. Lazdunski¹, C. Heurteaux¹

¹IPMC CNRS, Valbonne, France; ²Centre Recherche F. Seguin, Dpt Psychiatrie, Montréal, Canada;

³Laboratoire de Neuropharmacologie, Lyon 1, Lyon, France; ⁴DSPB Paris 5, Paris, France.

P 24. Plasma serotonin level of Vietnam war veterans with posttraumatic stress disorder and symptom severity

S. Hoon Kang, M. Yong Chung,

Department of Neuropsychiatry, Seoul Veterans Hospital, South Korea

P 25. Depression and anxiety in doctors of medicine

N. Ilic, V. Ilic

Health Center-Nis, Nis, Serbia

P 26. The relationship of sleep duration with suicide ideas in depressed individuals.

Weon Jeong Lim¹, Yu Jin Lee²

¹Department of psychiatry, Ewha Womans University Hospital, Seoul, Republic of Korea;

²Department of psychiatry, Gachon Medical School Gil Hospital, Incheon, Republic of Korea

P 27. Karolinska Interpersonal Violence (KIV) rating in suicide attempters

Jussi Jokinen, Marie Åsberg, Peter Nordström

Department of Clinical Neuroscience/Psychiatry, Karolinska Institutet, Stockholm, Sweden

P 28. Survival rates of maintenance treatment with Venlafaxine ER in patients with somatic symptoms

T. Jun, W. Bahk, H. Moon

Department of Psychiatry, College of Medicine, the Catholic University of Korea, Seoul, South Korea

P 29. Bipolar diathesis of unipolar treatment resistant depression

T. Jun, W. Bahk, H. Moon

Department of Psychiatry, College of Medicine, the Catholic University of Korea, Seoul, South Korea

P 30. Comparison of serum and urine analyses in CYP2D6 phenotyping for psychiatric purposes

J. Jurica¹, R. Bartecek², O. Zendulka¹, T. Kasperek², A. Zourkova², A. Sulcova¹

¹Masaryk University, Faculty of Medicine, Dept. of Pharmacology, Brno, Czech Republic; ²Dept.

of Psychiatry of Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

P 31. Relationship between opium abuse and the severity of depression in type II diabetic patients

A. Kord Valeshabad^{1,2}, Z. Sepehrmanesh³, H. Sarmast³

¹Tehran University of Medical Sciences (TUMS) - Student's Scientific Research Center (SSRC),

Tehran, Iran; ²National Foundation of Elites, Tehran, Iran, ³Kashan University of Medical Sciences - Department of endocrinology, Kashan, Iran



P 32. Escitalopram versus SNRIs as second-line treatment

Raymond W. Lam M.D¹, Sara Larsson Lönn Ph.D², Nicolas Despiégl M.Sc.³

¹Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; ²H Lundbeck A/S, Copenhagen, Denmark; ³Lundbeck SAS, Paris, France

P 33. Studying the impact of medication counselling for patients starting a treatment with antidepressant drugs

S. Liekens¹, V. Foulon¹, T. Smits², G. Laekeman¹

¹K.U.Leuven - Department of Pharmaceutical Sciences, Research centre for Pharmaceutical care and Pharmaco-economics, Leuven, Belgium; ²K.U.Leuven - European Centre for Ethics, Leuven, Belgium

P 34. Piracetam enhances psychostimulant methamphetamine effects and development of behavioural sensitization to it in mice

A. Machalova, K. Slais, D. Vrskova, A. Sulcova

Masaryk University, Faculty of Medicine - Department of Pharmacology, Brno, Czech Republic

P 35. The efficacy of quetiapine monotherapy in bipolar depression: combined data from the BOLDER and EMBOLDEN studies

J. Calabrese¹, K.A.N. Macritchie², A.H. Young², U. Gustafsson³, B. Paulsson³

¹University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, USA; ²University of British Columbia, Vancouver, Canada; ³AstraZeneca R&D, Södertälje, Sweden

P 36. The efficacy of quetiapine monotherapy in bipolar II depression: combined data from the BOLDER and EMBOLDEN studies

A.H. Young¹, K.A.N. Macritchie¹, J. Calabrese², U. Gustafsson³, B. Paulsson³, G.S. Malhi⁴, D.J. Bond¹, I.N. Ferrier⁵

¹University of British Columbia, Vancouver, Canada; ²University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, USA; ³AstraZeneca R&D, Södertälje, Sweden; ⁴CADE Clinic, Discipline of Psychological Medicine, University of Sydney, Sydney, Australia; ⁵Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

P 37. Duloxetine in the prevention of depressive recurrence: outcomes from the open-label acute and continuation study phases

M. Mancini¹, D. Perahia^{2,3}, M. Spann⁴, F. Wang⁴, D. Walker⁴, C. Yang⁴, M. Detke^{5,6,7}

¹Eli Lilly Italia SpA, Florence, Italy; ²Lilly Research Centre, Windlesham, UK; ³The Gordon Hospital, London, UK; ⁴Lilly Research Laboratories, Indianapolis, IN, USA ⁵MedAvante, Hamilton, NJ, USA; ⁶McLean Hospital/Harvard Medical School, Boston, MA, USA; ⁷Indiana University School of Medicine, Indianapolis, IN, USA

P 38. Review of prolactin levels in patients taking duloxetine

A.L. Montejo¹, A. Crucitti², D. G.S. Perahia^{2,3}, Q. Zhang⁴, Fujun Wang⁵, D. J. Walker⁴, M. Mancini⁶, S. Brecht⁷

¹Hospital Universitario de Salamanca, Salamanca, Spain; ²Lilly Research Centre, Windlesham, UK; ³The Gordon Hospital, London, UK; ⁴Lilly Research Laboratories, Indianapolis, Indiana, USA; ⁵Lilly USA, LLC, Indianapolis, Indiana, USA; ⁶Eli Lilly Italia SpA, Florence, Italy; ⁷Boehringer Ingelheim GmbH, Ingelheim, Germany



P 39. Extended release quetiapine fumarate monotherapy in patients with MDD: a pooled analysis of sustained response data from studies D1448C00001 and D1448C00002

S. Montgomery¹, R.S. McIntyre², J. Szamosi³, H.A. Eriksson³, W. Earley⁴

¹Imperial College School of Medicine, University of London, London, UK; ²University Health Network, Toronto, Canada; ³AstraZeneca R&D, Södertälje, Sweden; ⁴AstraZeneca Pharmaceuticals, Wilmington, USA

P 40. Efficacy of extended release quetiapine fumarate: pooled analysis in patients with severe generalised anxiety disorder

S. Montgomery¹, J. Locklear², H. Svedsäter³, H. Eriksson³

¹Imperial College School of Medicine, University of London, London, UK; ²AstraZeneca Pharmaceuticals, Wilmington, USA; ³AstraZeneca R&D, Mölndal, Sweden

P 41. Thyroid hormones affect recovery from depression during antidepressant treatment

C. Pae^{1,2}

¹Department of Psychiatry, Holy Family Hospital, The Catholic University of Korea College of Medicine, Bucheon, South Korea; ²Department of Psychiatry and Behavioral Medicines, Duke University Medical Center, Durham, USA

P 42. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study

C. Pae^{1,2}

¹Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, South Korea; ²Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, USA

P 43. Adherence to antidepressant treatment in Korea ; an analysis of national insurance data

J. Paik¹, K. Kim², S. Lee², W. Lim³, N. Kim⁴

¹Kyunghee university medical center, Seoul, South Korea; ²Research & development Center, Health Assurance Review and Assessment Agency, Seoul, South Korea; ³Ehwa university college of medicine, Seoul, South Korea; ⁴Dongkuk University college of medicine, Kyungju, South Korea

P 44. Efficacy and tolerability of escitalopram in patients suffering from depression with or without comorbid disorders

A. Kodounis¹, S. Stamouli², D. Vlisidis³, A. Karavatos⁴, E. Papalex⁵, I.A. Parashos⁵

¹251 Airforce General Hospital of Athens, Department of Neurology, Athens, Greece; ²University of Athens Eginition Hospital, 1st Psychiatric Dept, Athens, Greece; ³Asklepion General Hospital of Voula, Athens, Greece; ⁴Papageorgiou Regional General Hospital of Thessalonica, Dept of Neurology, Thessalonica, Greece; ⁵Lundbeck Hellas S.A., Athens, Greece

P 45. Social anxiety symptoms and other phobic symptoms in a sample of alcohol dependent individuals

T. Paparrigopoulos¹, E. Tzavellas², D. Karaikos³, I. Liappas⁴

¹Eginitio Hospital, University of Athens, Athens, Greece; ²Eginitio Hospital, University of Athens, Athens, Greece; ³Eginitio Hospital, University of Athens, Athens, Greece; ⁴Eginitio Hospital, University of Athens, Athens, Greece



P 46. Are old-old patients with MDD more likely to relapse than the young-old after open label treatment with escitalopram?

C. Katona¹, C.G. Lyketsos², M. Steinberg², S. Qureshi³, E. Weiller³, P. Gorwood⁴

¹Dept Mental Health Sciences, University College London, UK; ²Department of Psychiatry, School of Medicine, Johns Hopkins University and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA;

³H. Lundbeck A/S, Copenhagen, Denmark; ⁴INSERM U894, Sainte-Anne Hospital, Paris, France

P 47. Effects of new derivatives from phencyclidine on anxiety behaviours in adult male wistar rats

¹Jalal Solati, ²Abbas Ahmadi, ³Aliakbar Salari

¹Department of Biology, Faculty of Science, Islamic Azad University, Karaj branch, Karaj, Iran; ²Department of Chemistry, Faculty of Science, Islamic Azad University, Karaj branch, Karaj, Iran; ³Department of Biology, Faculty of Science, Islamic Azad University, North Tehran branch, Tehran, Iran

P 48. Psychosocial factors of postnatal depression. A longitudinal study

M. Serrano, M. Gili, N. Bauza, M. Vives, S. Monzon, M. Roca

University of Balearic Islands. Institut Universitari d'Investigació en Ciències de la Salut, Palma de Mallorca, Spain

P 49. Life events and social support during pregnancy: relationship to depressive symptoms in the immediate postpartum

M. Serrano¹, N. Bauza¹, M. Gili¹, S. Monzon¹, M. Vives¹, M.J. Martin-Vazquez², M. Roca¹

¹University of Balearic Islands. Institut Universitari d'Investigació en Ciències de la Salut, Palma de Mallorca, Spain; ²Rodríguez Lafora Hospital, Madrid, Spain

P 50. Efficacy of extended release quetiapine fumarate (quetiapine XR) in patients with severe major depressive disorder (MDD)

H. Svedäter¹, M. Thase², J. Locklear³, C. Datto³

¹AstraZeneca R&D, Mölndal, Sweden; ²Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA; ³AstraZeneca Pharmaceuticals, Wilmington, USA

P 51. Effects of extended release quetiapine fumarate (Quetiapine XR) on patient-reported outcomes in patients with generalised anxiety disorder (GAD)

H. Svedäter¹, J. Endicott², J. Locklear³

¹AstraZeneca R&D, Mölndal, Sweden; ²Department of Psychiatry, Columbia University, New York, USA; ³AstraZeneca Pharmaceuticals, Wilmington, USA

P 52. Staging of formation of co-morbidity of anxiety and depressive disorders as a factor determining the therapeutic strategy

S.N. Vasilyeva, G.G. Simutkin

Mental Health Research Institute, Tomsk, Russia



P 53. Maintenance treatment with quetiapine added to either lithium or divalproex in bipolar I disorder

E. Vieta¹, T. Suppes², U. Gustafsson³, B. Paulsson³

¹Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Barcelona, Spain; ²Department of Psychiatry and Behavioral Sciences, Stanford Medical Center and VA Palo Alto Health Care System, Palo Alto, USA; ³AstraZeneca R&D, Södertälje, Sweden

P 54. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder

E. Vieta¹, T. Suppes², U. Gustafsson³, P. Paulsson³

¹Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Barcelona, Spain; ²Department of Psychiatry and Behavioral Sciences, Stanford Medical Center and VA Palo Alto Health Care System, Palo Alto, USA; ³AstraZeneca R&D, Södertälje, Sweden

P 55. Extended release quetiapine fumarate (quetiapine XR) in acute and maintenance studies in major depressive disorder (MDD): suicidality data

R. Weisler¹, S.A. Montgomery², H.A. Eriksson³, J. Szamosi³

¹University of North Carolina at Chapel Hill, Duke University Medical Center, Durham, USA; ²Imperial College School of Medicine, University of London, London, UK; ³AstraZeneca R&D, Södertälje, Sweden

P 56. Novel selective anxiolytic afobazol prevents stress-induced decrease of benzodiazepine binding

M.A. Yarkova, K. Chekina, S.B. Seredenin

Zakusov's Research Institute of Pharmacology of RAMS, Moscow, Russia

P 57. Is depression a potential risk factor of metabolic syndrome in women?

D. Yoon

Seoul National University Hospital, Gangnam Center, Seoul, South Korea

P 58. Transcranial direct current stimulation (TDCS) in patients with major depressive episode

S. Zanoni¹, F. Castellano¹, N. D'urso¹, C. Dobrea¹, B. Benatti¹, C. Arici¹, R. Ferrucci², M. Vergari², B. Dell'osso¹, A. Priori², A.C. Altamura¹

¹Department of Psychiatry, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy; ²Centro Clinico per Neuronanotecnologie e la Neurostimolazione, Fond. IRCCS Osp. Maggiore Policlinico Dip Sc. Neurologiche, Milan, Italy



SCIENTIFIC INFORMATION

• Audio-Visual Facilities

Equipment for computerised Power Point presentations is provided during the scientific sessions. CD-Rom or USB key for Power Point presentations can be tested prior to presentation in the Multimedia Slide Center. CD-Rom or USB key must be handed over to the Multimedia Slide Center technicians at least forty minutes before the beginning of the sessions and must be collected directly by the speakers at the end of the session.

It is essential for the smooth running of the sessions that all the speakers hand in their Power Point presentation in due time.

• European Accreditation

15 European UEMS (European Union of Medical Specialists) credits have been recognized for this Forum.

• Certificate of Attendance

A certificate of attendance is provided, on request, at the registration desk on the last day of the Forum.

GENERAL INFORMATION

The “9th International Forum on Mood and Anxiety Disorders” is held at the Fairmont Hotel from 11-13 November 2009.

Admission

The participant's name badge is provided at the registration desk. All participants are requested to wear the badge throughout the congress. Only badge holders are admitted to the appropriate sessions, exhibition and social events.

Electricity

The standard voltage in Monaco is 220 V.

Insurance

The Congress organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice as you register for the Congress and book your travel.



Language

The official language of the Congress is English. No simultaneous translation is provided.

Secretariat

The secretariat desk will open on Wednesday, November 11 and stay open all through the Forum as follows:

• Wednesday, November 11	12.00 - 20.00
• Thursday, November 12	08.15 - 18.00
• Friday, November 13	08.15 - 16.30

What to do in Monaco

Sites and attractions

Situated in the far south-east corner of France, the Principality of Monaco stretches along a narrow four kilometres strip of coast, along the Mediterranean Sea, at the foot of the Southern Alps. The Principality has many interesting attractions: the Exotic Gardens, the Japanese Gardens situated right alongside the Mediterranean, and also the tourist train which will take you to explore the streets of Monaco. Visit the Old town where you can discover, in the narrow medieval alleyways, the Picturesque Place of Saint Nicolas and placette Bosio, the Cathedral, the Prince's Palace and the Changing of the Guards which takes place every day at 11.55.

Museums

- The Oceanographic Museum dedicated to Marine science and rare species of fish.
- The Wax museum depicting the history of Monaco's princes and scenes from the Grimaldi dynasty.
- The Exhibition of H.S.H. the Prince of Monaco's private collection of classic cars: a collection of around 100 vehicles of all ages.
- The Museum of Napoleonic Souvenirs: a collection of objects and documents relating to the 1st Empire.
- The Naval Museum displaying over 180 models of famous boats.
- The Museum of Prehistoric Anthropology with its collection of human and extinct animal remains from the archeological excavations of the region.



ANNOUNCEMENT OF NEXT FORUM

The 10th International Forum on Mood and Anxiety Disorders

will be held in Vienna, Austria
from 17-19 November 2010

**Save the date
17-19 NOVEMBER
2010**

10th INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

VIENNA, 17-19 NOVEMBER, 2010



www.ifmad.org





JARDINS PUBLICS

- A** Jardins du Casino (C3)
- B** Jardins du Larvotto (L3)
- C** Jardin Japonais (A3)
- D** Jardin Saint-Martin (C5)
- E** Parc Paysager de Fontvieille et Forêt Princesse Grace (B5)
- F** Parc Princesse Antoinette (C5)

ADRESSES UTILES

- 1** Agence Commerciale Monaco Telecom (B3)
- 2** Automobile Club (E3)
- 3** Bibliothèque Louis-Nolani (D3)
- 4** Capitaine du Port Hercule (F3)
- 5** 6, Quai Antoine 1^{er}
- 6** Capitaine du Port de Fontvieille (C5)
- 7** Audiotour Rainer III (C4)
- 8** Centre de Rencontres Internationales (F3)
- 9** Théâtre Princesse Grace (F3)
- 10** Grimaldi Forum (L3)
- 11** Conseil National (C5)
- 12** Direction du Tourisme et des Congrès (C2)
- 13** Espace Fontvieille "Chapiteau" (B5)
- 14** Gare de Monaco-Monte-Carlo (C2)
- 15** Héliport de Monaco (B5)
- 16** Mairie (D5)
- 17** Ministère d'État (D5)
- 18** Monte-Carlo Sporting Club (L3)
- 19** Office des Emissions de Timbres-poste (C3)
- 20** Palais de Justice (C5)
- 21** Palais Maritime (E5)
- 22** Police Maritime (E5)
- 23** Police Santé Publique (D3)
- 24** Sporting d'Hiver (C3)
- 25** Yacht Club (E5)

CENTRES ATTRACTIFS ET CULTURELS

- 1** Casino - Salle Garnier (C3)
- 2** Cathédrale (C5)
- 3** Centre d'Acclimatation Zoologique (C3)
- 4** Église Sainte-Devote (E2)
- 5** Histoire des Princes de Monaco (D4)
- 6** Musée de la Croix
- 7** Jardin Exotique et Grotte de l'Observatoire (B2)
- 8** Musée d'Anthropologie Préhistorique (B5)
- 9** Musée Océanographique et Aquarium (D5)
- 10** Monte-Carlo Story (D5)
- 11** Musée National
- 12** Musée des Monnaies d'Europe (L2)
- 13** Musée des Souverains Norvégiens
- 14** Musée des Archives Historiques du Palais (C4)
- 15** Musée du Vieux Monaco (C4)
- 16** Palais Princier - Place du Palais
- 17** Grands Appartements (en été seulement) (C4)
- 18** Stade Louis II (A4)
- 19** Théâtre du Fort Antoine (E5)
- 20** Musée de la Marine (B5)
- 21** Monaco Top Cars (Musée de l'Automobile)
- 22** Musée de la Chapelle de la Vocation (D5)
- 23** Musée des Timbres et des Monnaies

HOTELS

- 1** Hôtel Fairmont ***"Luxe"
- 2** Novotel Monte-Carlo ***

LEGENDES DES SYMBOLES

- 1** Ascenseurs publics
- 2** Parking publics
- 3** Parking autorisés
- 4** Stations de taxis
- 5** Bureaux de Poste
- 6** Rue piétonne
- 7** Taxis

Tél. 93.15.01.01



Cipralex - the power to tackle depression at its core

Leaving no one behind

Presentation: "Cipralex". Tablets containing 5, 10, 15 or 20 mg escitalopram (as oxalate). **Indications:** Major depression. Generalised anxiety disorder. Panic disorder. Social anxiety disorder. Obsessive compulsive disorder. **Dosage:** Usual dose is 10 mg daily. Maximum dose 20 mg daily. In elderly (>65 years), in panic disorder patients and in patients with reduced hepatic function an initial dose of 5 mg daily is recommended. Caution in patients with severely reduced renal function. Not recommended in children

and adolescents (<18 years). When stopping treatment the dose should be gradually reduced over a period of one or two weeks. **Contraindications:** Hypersensitivity to escitalopram. Concomitant treatment with MAOIs. **Pregnancy and lactation:** Careful consideration prior to use in pregnant women. Breast-feeding women should not be treated. **Precautions:** The special warnings and precautions which apply to the class of SSRIs. **Drug interactions:** MAOIs, serotonergic drugs, drugs lowering the seizure threshold, lithium

tryptophan, St. John's Wort, anticoagulants, drugs metabolised mainly by enzymes CYP 2D6 or 2C19. **Adverse events:** Most frequent during the first or second week, very common is nausea, less frequent is adverse events comprising to the SSRI class. **Overdosage:** Doses between 400 mg and 800 mg of escitalopram alone have been taken without any severe symptoms. Consult full prescribing information before prescribing. H. Lundbeck A/S, Copenhagen, Denmark. Date of preparation: May 2009

Lundbeck



Cipralex
escitalopram